{"id":"131i-ipa","safety":{"commonSideEffects":[{"rate":"30%","effect":"Nausea"},{"rate":"20%","effect":"Vomiting"},{"rate":"15%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"131I-IPA is a radioligand that targets the somatostatin receptor, allowing for targeted delivery of radiation to cancer cells.","oneSentence":"Iodine-131 labelled peptide for targeted radionuclide therapy","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:47:55.085Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer"},{"name":"Neuroendocrine tumors"}]},"trialDetails":[{"nctId":"NCT07100730","phase":"PHASE3","title":"Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2025-11-02","conditions":"Neoplastic Disease, Glioblastoma, Glioblastoma (GBM)","enrollment":50},{"nctId":"NCT05450744","phase":"PHASE1","title":"131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2023-04-01","conditions":"Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme","enrollment":12},{"nctId":"NCT03849105","phase":"PHASE1, PHASE2","title":"131I-IPA and Concurrent XRT in Recurrent GBM","status":"COMPLETED","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2019-04-09","conditions":"Glioblastoma Multiforme","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["18F-FET"],"phase":"phase_1","status":"active","brandName":"131I-IPA","genericName":"131I-IPA","companyName":"Telix Pharmaceuticals (Innovations) Pty Limited","companyId":"telix-pharmaceuticals-innovations-pty-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iodine-131 labelled peptide for targeted radionuclide therapy Used for Prostate cancer, Neuroendocrine tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}